Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

ClinicalTrials.gov ID: NCT00375284

Public ClinicalTrials.gov record NCT00375284. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome

Study identification

NCT ID
NCT00375284
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
404 participants

Conditions and interventions

Interventions

  • Pramipexole Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2006
Primary completion
Jun 30, 2007
Completion
Not listed
Last update posted
Oct 30, 2013

Started 2006

United States locations

U.S. sites
52
U.S. states
25
U.S. cities
50
Facility City State ZIP Site status
248.616.065 Boehringer Ingelheim Investigational Site Birmingham Alabama
248.616.028 Boehringer Ingelheim Investigational Site Dothan Alabama
248.616.035 Boehringer Ingelheim Investigational Site Mesa Arizona
248.616.025 Boehringer Ingelheim Investigational Site Peoria Arizona
248.616.073 Boehringer Ingelheim Investigational Site Phoenix Arizona
248.616.067 Boehringer Ingelheim Investigational Site Tucson Arizona
248.616.009 Boehringer Ingelheim Investigational Site Fayetteville Arkansas
248.616.040 Boehringer Ingelheim Investigational Site Foothill Ranch California
248.616.062 Boehringer Ingelheim Investigational Site Fullerton California
248.616.050 Boehringer Ingelheim Investigational Site Pasadena California
248.616.031 Boehringer Ingelheim Investigational Site Colorado Springs Colorado
248.616.017 Boehringer Ingelheim Investigational Site Pueblo Colorado
248.616.071 Boehringer Ingelheim Investigational Site Wallingford Connecticut
248.616.043 Boehringer Ingelheim Investigational Site DeLand Florida
248.616.014 Boehringer Ingelheim Investigational Site Jacksonville Florida
248.616.020 Boehringer Ingelheim Investigational Site Naples Florida
248.616.048 Boehringer Ingelheim Investigational Site Pembroke Pines Florida
248.616.072 Boehringer Ingelheim Investigational Site Spring Hill Florida
248.616.018 Boehringer Ingelheim Investigational Site St. Petersburg Florida
248.616.049 Boehringer Ingelheim Investigational Site Augusta Georgia
248.616.033 Boehringer Ingelheim Investigational Site Columbus Georgia
248.616.057 Boehringer Ingelheim Investigational Site Macon Georgia
248.616.066 Boehringer Ingelheim Investigational Site Savannah Georgia
248.616.047 Boehringer Ingelheim Investigational Site Stockbridge Georgia
248.616.059 Boehringer Ingelheim Investigational Site Chicago Illinois
248.616.045 Boehringer Ingelheim Investigational Site Lenexa Kansas
248.616.061 Boehringer Ingelheim Investigational Site Olathe Kansas
248.616.060 Boehringer Ingelheim Investigational Site Baton Rouge Louisiana
248.616.058 Boehringer Ingelheim Investigational Site Brighton Massachusetts
248.616.051 Boehringer Ingelheim Investigational Site Wellesley Hills Massachusetts
248.616.001 Boehringer Ingelheim Investigational Site Minneapolis Minnesota
248.616.004 Boehringer Ingelheim Investigational Site Jackson Mississippi
248.616.064 Boehringer Ingelheim Investigational Site Florissant Missouri
248.616.016 Boehringer Ingelheim Investigational Site St Louis Missouri
248.616.063 Boehringer Ingelheim Investigational Site St Louis Missouri
248.616.053 Boehringer Ingelheim Investigational Site Dover New Hampshire
248.616.036 Boehringer Ingelheim Investigational Site Albuquerque New Mexico
248.616.021 Boehringer Ingelheim Investigational Site Albany New York
248.616.013 Boehringer Ingelheim Investigational Site Cincinnati Ohio
248.616.003 Boehringer Ingelheim Investigational Site Cleveland Ohio
248.616.068 Boehringer Ingelheim Investigational Site Marion Ohio
248.616.012 Boehringer Ingelheim Investigational Site Norman Oklahoma
248.616.006 Boehringer Ingelheim Investigational Site Oklahoma City Oklahoma
248.616.019 Boehringer Ingelheim Investigational Site Oklahoma City Oklahoma
248.616.069 Boehringer Ingelheim Investigational Site Clarks Summit Pennsylvania
248.616.008 Boehringer Ingelheim Investigational Site Columbia South Carolina
248.616.005 Boehringer Ingelheim Investigational Site Dallas Texas
248.616.070 Boehringer Ingelheim Investigational Site Rockwall Texas
248.616.039 Boehringer Ingelheim Investigational Site San Marcos Texas
248.616.011 Boehringer Ingelheim Investigational Site Alexandria Virginia
248.616.055 Boehringer Ingelheim Investigational Site Norfolk Virginia
248.616.024 Boehringer Ingelheim Investigational Site Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00375284, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 30, 2013 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00375284 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →